<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39540209</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France.</ArticleTitle><Pagination><StartPage>2423474</StartPage><MedlinePgn>2423474</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2423474</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2024.2423474</ELocationID><Abstract><AbstractText>An evaluation was conducted to predict the economic and clinical burden of vaccinating all immunocompromised (IC) individuals aged&#x2009;&#x2265;30&#x2009;years with mRNA-1273 variant-adapted COVID-19 vaccines versus BNT162b2 variant-adapted vaccines in Fall 2023 and Spring 2024 in France. The number of symptomatic SARS-CoV-2 infections, hospitalizations or deaths due to COVID-19, and long COVID cases, costs and quality-adjusted life years (QALYs) were estimated using a static decision-analytic model. Predicted vaccine effectiveness (VE) were based on real-world data from the original and BA.4/5 variant-adapted vaccines, suggesting higher protection against infection and hospitalization with mRNA-1273 vaccines. VE estimates were combined with COVID-19 incidence and probability of COVID-19 severe outcomes. Uncertainty surrounding VE, vaccine coverage, infection incidence, hospitalization and mortality rates, costs and QALYs were evaluated in sensitivity analyses. In an ideal situation where 100% coverage is achieved, the mRNA-1273 variant-adapted vaccine is predicted to prevent an additional 3,882 infections, 357&#xa0;hospitalizations, 81 deaths, and 326 long COVID cases when compared to BNT162b2 variant-adapted vaccines in 230,000 IC individuals. This translates to &#x20ac;10.1 million cost-savings from a societal perspective and 645 QALYs gained. Results were consistent across all analyses and most sensitive to variations surrounding VE and coverage. These findings highlight the importance of increasing vaccine coverage, and ability to induce higher levels of protection with mRNA-1273 formulations in this vulnerable population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Quadrant Health Economics Inc, Cambridge, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davido</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Maladies Infectieuses, H&#xf4;pital Universitaire Raymond-Poincar&#xe9;, AP-HP Universit&#xe9; Paris Saclay, Garches, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck</LastName><ForeName>Ekkehard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Health Economics and Outcomes Research, Moderna Inc, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demont</LastName><ForeName>Clarisse</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Health Economics and Outcomes Research, Moderna France, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Keya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Health Economics and Outcomes Research, Moderna Inc, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohli</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Quadrant Health Economics Inc, Cambridge, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maschio</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Quadrant Health Economics Inc, Cambridge, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uhart</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Health Economics and Outcomes Research, Moderna France, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Mouaddin</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Health Economics and Outcomes Research, Moderna France, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EPK39PL4R4</RegistryNumber><NameOfSubstance UI="D000090983">2019-nCoV Vaccine mRNA-1273</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="Y">Immunocompromised Host</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="Y">BNT162 Vaccine</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090983" MajorTopicYN="Y">2019-nCoV Vaccine mRNA-1273</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="Y">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="N">Vaccine Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">COVID-19&#xa0;hospitalization</Keyword><Keyword MajorTopicYN="N">France</Keyword><Keyword MajorTopicYN="N">decision analysis</Keyword><Keyword MajorTopicYN="N">economic modeling</Keyword><Keyword MajorTopicYN="N">vaccine effectiveness</Keyword></KeywordList><CoiStatement>MK is a shareholder in Quadrant Health Economics, Inc., which was contracted by Moderna, Inc, to conduct this study. AL and MM are consultants at Quadrant Health Economics, Inc. CD, NE and MU are employees of Moderna France and hold stock/stock options in the company. KJ and EB are employees of Moderna, Inc., and hold stock/stock options in the company. BD received fees for consultation from Moderna France.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>14</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>14</Day><Hour>17</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>14</Day><Hour>4</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39540209</ArticleId><ArticleId IdType="pmc">PMC11572258</ArticleId><ArticleId IdType="doi">10.1080/21645515.2024.2423474</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tan-Lhernould L, Tamandjou C, Deschamps G, Platon J, Sommen C, Chereau F, Parent du Ch&#xe2;telet I, Cauchemez S, Vaux S, Paireau J.. Impact of vaccination against severe COVID-19 in the French population aged 50 years and above: a retrospective population-based study. BMC Med. 2023;21(1):426. doi:10.1186/s12916-023-03119-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-023-03119-8</ArticleId><ArticleId IdType="pmc">PMC10633992</ArticleId><ArticleId IdType="pubmed">37940955</ArticleId></ArticleIdList></Reference><Reference><Citation>Opinions of the vaccine strategy steering committee. January 14, 2021. [accessed 2023 Dec
15]. https://sante.gouv.fr/soins-et-maladies/maladies/maladies-infectieuses/coronavirus/vaccin-covid-19/article/les-avis-du-conseil-d-orientation-de-la-strategie-vaccinale.</Citation></Reference><Reference><Citation>Opinion on simplification, expansion and acceleration of the covid-19 vaccination campaign. January 6, 2021. [accessed 2023 Dec
15]. https://sante.gouv.fr/soins-et-maladies/maladies/maladies-infectieuses/coronavirus/vaccin-covid-19/article/les-avis-du-conseil-d-orientation-de-la-strategie-vaccinale.</Citation></Reference><Reference><Citation>COVID-19 vaccine tracker. [accessed 2023 Nov
30]. https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#age-group-tab.).</Citation></Reference><Reference><Citation>Avis du 6 avril 2021 : Elargissement des priorit&#xe9;s d&#x2019;acc&#xe8;s &#xe0; la vaccination anti Covid-19. [accessed 2023 Dec
5]. https://sante.gouv.fr/IMG/pdf/avis_du_cosv_6_avril_2021pdf.pdf.</Citation></Reference><Reference><Citation>de Prost N, Audureau E, Heming N, de Prost N, Gault E, Pham T, Chaghouri A, de Montmollin N, Voiriot G, Morand-Joubert L, et al. Clinical phenotypes and outcomes associated with SARS-CoV-2 variant omicron in critically ill French patients with COVID-19. Nat Commun. 2022;13(1):6025. doi:10.1038/s41467-022-33801-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33801-z</ArticleId><ArticleId IdType="pmc">PMC9555693</ArticleId><ArticleId IdType="pubmed">36224216</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng HF, Ackerson BK, Sy LS, Tubert JE, Luo Y, Qiu S, Lee GS, Bruxvoort KJ, Ku JH, Florea A, et al. mRNA-1273 bivalent (original and omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States. Nat Commun. 2023;14(1):5851. doi:10.1038/s41467-023-41537-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-41537-7</ArticleId><ArticleId IdType="pmc">PMC10511551</ArticleId><ArticleId IdType="pubmed">37730701</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, Tay SH, Teo CB, Tan BKJ, Chan YH, et al. Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632. doi:10.1136/bmj-2021-068632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068632</ArticleId><ArticleId IdType="pmc">PMC8889026</ArticleId><ArticleId IdType="pubmed">35236664</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof SY, Slezak JM, Puzniak L, Hong V, Xie F, Ackerson BK, Valluri SR, Jodar L, McLaughlin JM. Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants. Lancet Respir Med. 2022;10(7):e61&#x2013;12. doi:10.1016/S2213-2600(22)00170-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00170-9</ArticleId><ArticleId IdType="pmc">PMC9075856</ArticleId><ArticleId IdType="pubmed">35533699</ArticleId></ArticleIdList></Reference><Reference><Citation>Spikevax (previously COVID-19 vaccine moderna): EPAR - Product information. Annex I. Summary of product characteristics. [accessed 2024 Feb
23]. https://www.ema.europa.eu/en/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf.).</Citation></Reference><Reference><Citation>Aberumand B, Ayoub Goulstone W, Betschel S. Understanding attitudes and obstacles to vaccination against COVID-19 in patients with primary immunodeficiency. Allergy Asthma Clin Immunol. 2022;18(1):38. doi:10.1186/s13223-022-00679-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13223-022-00679-x</ArticleId><ArticleId IdType="pmc">PMC9083475</ArticleId><ArticleId IdType="pubmed">35534860</ArticleId></ArticleIdList></Reference><Reference><Citation>MacEwan SR, Gaughan AA, Dixon GN, Olvera RG, Tarver WL, Rahurkar S, Rush LJ, Schenk AD, Stevens J, McAlearney AS. Understanding concerns about COVID-19 and vaccination: perspectives from kidney transplant recipients. Vaccines (Basel). 2023;11(7):11. doi:10.3390/vaccines11071134.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11071134</ArticleId><ArticleId IdType="pmc">PMC10386736</ArticleId><ArticleId IdType="pubmed">37514950</ArticleId></ArticleIdList></Reference><Reference><Citation>Moderna Inc. SPIKEVAX . (mRNA-1273) full prescribing information. 2022. https://static.modernatx.com/pm/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867/5efa7d9d-05e8-46b5-945a-637c2867bd00/5efa7d9d-05e8-46b5-945a-637c2867bd00_viewable_rendition__v.pdf.</Citation></Reference><Reference><Citation>Pfizer/BioNTech . COMIRNATY (BNT162b2) full prescribing information. 2022. https://labeling.pfizer.com/ShowLabeling.aspx?id=16351&amp;format=pdf.</Citation></Reference><Reference><Citation>Fact sheet for healthcare providers administering vaccine: emergency use authorization of moderna covid-19 vaccine, bivalent (original and omicron ba.4/ba.5). Moderna: Inc;  [accessed 2023 Aug
25]. https://eua.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf.).</Citation></Reference><Reference><Citation>Fact sheet for healthcare providers administering vaccine: emergency use authorization (EUA): pfizer-BioNTech COVID-19 vaccine, bivalent (original and omicron BA.4/BA.5) and booster dose for 12 years of age and older. Pfizer/BioNtech. 2022.  [Accessed Mar
7, at
https://www.fda.gov/media/167211/download.).</Citation></Reference><Reference><Citation>Nguyen VH, Boileau, C, Bogdanov A, Sredl M, Bonafede M, Ducruet T, Chavers S, Rosen A, Martin D, Buck P, et al. Relative effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines and homologous boosting in preventing COVID-19 in adults in the US. Open Forum Infect Dis. 2023;10(7):ofad288. doi:10.1093/ofid/ofad288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad288</ArticleId><ArticleId IdType="pmc">PMC10368199</ArticleId><ArticleId IdType="pubmed">37496607</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono S, Michihata N, Yamana H, Uemura K, Ono Y, Jo T, Yasunaga H. Comparative effectiveness of BNT162b2 and mRNA-1273 booster dose after BNT162b2 primary vaccination against the omicron variants: a retrospective cohort study using large-scale population-based registries in Japan. Clin Infect Dis. 2023;76(1):18&#x2013;24. doi:10.1093/cid/ciac763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac763</ArticleId><ArticleId IdType="pmc">PMC9494390</ArticleId><ArticleId IdType="pubmed">36124762</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayr FB, Talisa VB, Shaikh OS, Omer SB, Butt AA, Yende S. Comparative COVID-19 vaccine effectiveness over time in veterans. Open Forum Infect Dis. 2022;9(7):ofac311. doi:10.1093/ofid/ofac311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac311</ArticleId><ArticleId IdType="pmc">PMC9278190</ArticleId><ArticleId IdType="pubmed">35880233</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulme WJ, Horne EMF, Parker EPK, Keogh RH, Williamson EJ, Walker V, Palmer TM, Curtis HJ, Walker AJ, Andrews CD, et al. Comparative effectiveness of BNT162b2 versus mRNA-1273 COVID-19 vaccine boosting in England: matched cohort study in OpenSAFELY-tpp. BMJ. 2023;380:e072808. doi:10.1136/bmj-2022-072808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072808</ArticleId><ArticleId IdType="pmc">PMC10014664</ArticleId><ArticleId IdType="pubmed">36921925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopel H, Nguyen VH, Boileau C, Bogdanov A, Winer I, Ducruet T, Zeng N, Bonafede M, Esposito DB, Martin D, et al. Comparative effectiveness of bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 vaccines mRNA-1273.222 and BNT162b2 bivalent vaccine in adults in the US. Vaccines. 2023;11(11):1711. doi:10.3390/vaccines11111711.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11111711</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Haeussler K, Spellman A, Phillips LE, Ramiller A, Bausch-Jurken MT, Sharma P, Krivelyova A, Vats S, Van de Velde N. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework. Front Immunol. 2023;14:14. doi:10.3389/fimmu.2023.1204831.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1204831</ArticleId><ArticleId IdType="pmc">PMC10523015</ArticleId><ArticleId IdType="pubmed">37771594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavikondala S, Haeussler K, Wang X, Spellman A, Bausch-Jurken MT, Sharma P, Amiri M, Krivelyova A, Vats S, Nassim M, et al. Immunogenicity of mRNA-1273 and BNT162b2 in immunocompromised patients: systematic review and meta-analysis using GRADE. Infect Dis Ther. 2023;13(7):1419&#x2013;1438. doi:10.1007/s40121-024-00987-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-024-00987-2</ArticleId><ArticleId IdType="pmc">PMC11219657</ArticleId><ArticleId IdType="pubmed">38802704</ArticleId></ArticleIdList></Reference><Reference><Citation>Statement on the fifteenth meeting of the IHR . Emergency committee on the COVID-19 pandemic. 2005.  [Accessed 2023, Oct
2, at
https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-%282005%29-emergency-committee-regarding-the-coronavirus-disease-%28covid-19%29-pandemic.).</Citation></Reference><Reference><Citation>Campagne de vaccination contre le COVID-19 a L&#x2019;automne 2023. 2023. [Accessed 2023, Dec
5, at
https://sante.gouv.fr/IMG/pdf/dgs-urgent_no2023-17_-_campagne_de_vaccination_contre_le_covid-19_a_l_automne_23.pdf.).</Citation></Reference><Reference><Citation>SPIKEVAX (&#xe9;lasom&#xe9;ran/davesom&#xe9;ran/andusom&#xe9;ran) - COVID-19. [Accessed 2023, Dec
5, at
https://www.has-sante.fr/jcms/p_3466353/fr/spikevax-elasomeran-/-davesomeran-/-andusomeran-covid-19.).</Citation></Reference><Reference><Citation>Avis n&#xb0;2024.0001/AC/SESPEV du 08 f&#xe9;vrier 2024 du coll&#xe8;ge de la Haute Autorit&#xe9; de sant&#xe9; relatif &#xe0; la date de lancement de la campagne de vaccination au printemps 2024 contre la COVID-19 2024. [Accessed 2024, 2024 Feb
26, at
https://www.has-sante.fr/upload/docs/application/pdf/2024-02/avis_n20240001acsespev_du_08_fevrier_2024_du_college_de_la_has_relatif_a_la_date_de_lancement_de_la_campagne_de_vaccination_.pdf.).</Citation></Reference><Reference><Citation>COVID-19 vaccine renewal: protecting the most vulnerable. 2024. [Accessed 2024 Sep
24, at
https://sante.gouv.fr/soins-et-maladies/maladies/maladies-et-infections-respiratoires/coronavirus-11069/vaccin-covid-19/article/renouvellement-vaccinal-contre-le-covid-19-proteger-les-plus-fragiles.).</Citation></Reference><Reference><Citation>Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. Jama. 2021;326(15):1533&#x2013;1535. doi:10.1001/jama.2021.15125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.15125</ArticleId><ArticleId IdType="pmc">PMC8406205</ArticleId><ArticleId IdType="pubmed">34459863</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplonek P, Cizmeci D, Fischinger S, Collier A-R, Suscovich T, Linde C, Broge T, Mann C, Amanat F, Dayal D, et al. mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. Sci Transl Med. 2022;14(645):eabm2311. doi:10.1126/scitranslmed.abm2311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abm2311</ArticleId><ArticleId IdType="pmc">PMC8995030</ArticleId><ArticleId IdType="pubmed">35348368</ArticleId></ArticleIdList></Reference><Reference><Citation>Naranbhai V, Garcia-Beltran WF, Chang CC, Berrios Mairena C, Thierauf JC, Kirkpatrick G, Onozato ML, Cheng J, St Denis KJ, Lam EC, et al. Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 vaccines. J Infect Dis. 2022;225(7):1141&#x2013;1150. doi:10.1093/infdis/jiab593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab593</ArticleId><ArticleId IdType="pmc">PMC8689763</ArticleId><ArticleId IdType="pubmed">34888672</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinozuka J, Hata M, Eguchi H, Mori M, Eguchi M, Fukui M, Sai N, Imashuku S, Sueyoshi A. COVID-19 vaccination: effective utilization of low dead space (LDS) syringes. Int J Infect Dis. 2021;113:90&#x2013;92. doi:10.1016/j.ijid.2021.09.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.09.068</ArticleId><ArticleId IdType="pmc">PMC8479380</ArticleId><ArticleId IdType="pubmed">34600135</ArticleId></ArticleIdList></Reference><Reference><Citation>Pessoa-Gon&#xe7;alves YM, Jesus ALG, Desid&#xe9;rio CS, Minchio GA, Louzada ADS, Shimano MM, Oliveira CJF. Understanding the relationship between vaccine supply dead space and wasted COVID-19 vaccine doses. Rev Soc Bras Med Trop. 2023;56:e03532023. doi:10.1590/0037-8682-0353-2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0037-8682-0353-2023</ArticleId><ArticleId IdType="pmc">PMC10550090</ArticleId><ArticleId IdType="pubmed">37792841</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A, Jayasundara K, Kohli M, Maschio M, Fust K, Joshi K, van de Velde N, Beck E. Clinical and economic impact of updated Fall 2023 COVID-19 vaccines in the immunocompromised population in Canada. medRxiv. 2023;2023.11.10.23298369.</Citation></Reference><Reference><Citation>Conseil d&#x2019;Orientation de la Strat&#xe9;gie Vaccinale. Avis du 6 avril 2021: Elargissement des priorit&#xe9;s d&#x2019;acc&#xe8;s &#xe0; la vaccination anti-COVID-19 - mise &#xe0; jour 7 mai 2021. [Accessed 2023 Nov
20, at
https://sante.gouv.fr/IMG/pdf/avis_du_cosv_6_avril_2021pdf.pdf.</Citation></Reference><Reference><Citation>Health-related concerns and precautions during the COVID-19 pandemic: a comparison of Canadians with and without underlying health concerns. July 2, 2020. [accessed 2023 Apr
21] https://www150.statcan.gc.ca/n1/en/pub/82-003-x/2020005/article/00001-eng.pdf?st=fRIC98Ej.).</Citation><ArticleIdList><ArticleId IdType="pubmed">32644765</ArticleId></ArticleIdList></Reference><Reference><Citation>World Population Prospects . Online edition. Population by single age &#x2013; both sexes. 2022. 2022.  [Accessed 2023, Aug
2, at
https://population.un.org/wpp/Download/Standard/Population/.).</Citation></Reference><Reference><Citation>Kohli MA, Maschio M, Joshi K, Lee A, Fust K, Beck E, Van de Velde N, Weinstein MC. The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States. J Med Econ. 2023;26(1):1532&#x2013;1545. doi:10.1080/13696998.2023.2281083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13696998.2023.2281083</ArticleId><ArticleId IdType="pubmed">37961887</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratama NR, Wafa IA, Budi DS, Sutanto H, Asmarawati TP, Barlian Effendi G, Wungu CDK. Effectiveness of COVID-19 vaccines against SARS-CoV-2 omicron variant (B.1.1.529): a systematic review with meta-analysis and meta-regression. Vaccines. 2022;10(12):2180. doi:10.3390/vaccines10122180.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10122180</ArticleId><ArticleId IdType="pmc">PMC9783108</ArticleId><ArticleId IdType="pubmed">36560590</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R, Ciesla AA, Mak J, Miller JD, Silk BJ, Lambrou AS, Paden CR, Shirk P, Britton A, Smith ZR, et al. Early estimates of updated 2023&#x2013;2023 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to Co-circulating omicron variants among immunocompetent adults &#x2014; increasing community access to testing program, United States, September 2023&#x2013;January 2024, United States, September MMWR Morbidity And Mortal Wkly Report 2024. 2024; 73(4):77&#x2013;83. doi:10.15585/mmwr.mm7304a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7304a2</ArticleId><ArticleId IdType="pmc">PMC10843065</ArticleId><ArticleId IdType="pubmed">38300853</ArticleId></ArticleIdList></Reference><Reference><Citation>Higdon MM, Baidya A, Walter KK, Patel MK, Issa H, Espi&#xe9; E, Feikin DR, Knoll MD. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant. Lancet Infect Dis. 2022;22(8):1114&#x2013;1116. doi:10.1016/S1473-3099(22)00409-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00409-1</ArticleId><ArticleId IdType="pmc">PMC9221361</ArticleId><ArticleId IdType="pubmed">35752196</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopel H, Nguyen VH, Bogdanov A, Winer I, Boileau C, Ducruet T, Bausch-Jurken M, Esposito D.B, Beck E, Bonafede M. Comparative effectiveness of the bivalent COVID-19 mRNA vaccines, mRNA1273-222 and BNT162b2, in immunocompromised adults in the US. J Clin Oncol. 2024;42(16 suppl):e23057. doi:10.1200/JCO.2024.42.16_suppl.e230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2024.42.16_suppl.e230</ArticleId></ArticleIdList></Reference><Reference><Citation>Demographic balance sheet 2020: survivors. 2020. [Accessed 2023, Mar
10, at
https://www.insee.fr/en/statistiques/5235015?sommaire=501592.).</Citation></Reference><Reference><Citation>Boehmer TK, Kompaniyets L, Lavery AM, Hsu J, Ko JY, Yusuf H, Romano SD, Gundlapalli AV, Oster ME, Harris AM. Association between COVID-19 and myocarditis using hospital-based administrative data &#x2014; United States, March 2020&#x2013;January 2020, March MMWR Morbidity And Mortal Wkly Report 2021. 2021. Jan 2021. 70(35):1228&#x2013;1232. doi:10.15585/mmwr.mm7035e5.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7035e5</ArticleId><ArticleId IdType="pmc">PMC8422872</ArticleId><ArticleId IdType="pubmed">34473684</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahremand T, Yao JA, Mill C, Piszczek J, Grant JM, Smolina K. COVID-19&#xa0;hospitalisations in immunocompromised individuals in the omicron era: a population-based observational study using surveillance data in British Columbia, Canada. Lancet Reg Health - Americas. 2023;20:100461. doi:10.1016/j.lana.2023.100461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2023.100461</ArticleId><ArticleId IdType="pmc">PMC9987330</ArticleId><ArticleId IdType="pubmed">36890850</ArticleId></ArticleIdList></Reference><Reference><Citation>Turtle L, Thorpe M, Drake TM, Swets M, Palmieri C, Russell CD, Ho A, Aston S, Wootton DG, Richter A, et al. Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study. PLOS Med. 2023;20(1):e1004086. doi:10.1371/journal.pmed.1004086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1004086</ArticleId><ArticleId IdType="pmc">PMC9928075</ArticleId><ArticleId IdType="pubmed">36719907</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#x2019;affection post-COVID-19 (appel&#xe9;e aussi COVID long) en France. Point au 21 juillet 2022. [Accessed 2023, Apr
6, at
https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/enquetes-etudes/l-affection-post-covid-19-appelee-aussi-covid-long-en-france.-point-au-21-juillet-2022.).</Citation></Reference><Reference><Citation>Recommendations vaccinales pour l&#x2019;annee 2023. 2023. [Accessed 2023, Dec
6, at
https://sante.gouv.fr/IMG/pdf/dgs-urgent_no2023_07_strategie_vaccinale_covid_2023.pdf.).</Citation></Reference><Reference><Citation>R&#xe9;seau Sentinelle . [Accessed 2023, Apr
6, at
https://www.sentiweb.fr/france/fr/?page=covid19.).</Citation></Reference><Reference><Citation>Rapport d&#x2019;&#xe9;valuation des politiques de s&#xe9;curit&#xe9; sociale (REPSS) Annexe 1 Maladie. 2023. (Accessed 2024, at
https://evaluation.securite-sociale.fr/files/live/sites/Repss/files/M%c3%a9diath%c3%a8que/Maladie/PLACSS_REPSS%202022_Maladie.pdf.).</Citation></Reference><Reference><Citation>WHO . Guide for standardization of economic evaluations of immunization programmes. 2nd ed. Geneva: World Health Organization; 2019.</Citation></Reference><Reference><Citation>Public Health Agency of Canada . National advisory committee on immunization (NACI) guidelines for the economic evaluation of vaccination programs in Canada. 2023.  [accessed 2023 Oct 10]. https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/methods-process/incorporating-economic-evidence-federal-vaccine-recommendations/guidelines-evaluation-vaccination-programs-canada.pdf.</Citation></Reference><Reference><Citation>Vaccines and Related Biological Products Advisory Committee . Moderna COVID-19 variant vaccines. Moderna, Inc. June 15, 2023. (Accessed 2023 Oct
10, at https://www.fda.gov/media/169539/download.).</Citation></Reference><Reference><Citation>Chalkias S, McGhee N, Whatley JL, Essink B, Brosz A, Tomassini JE, Girard B, Edwards DK, Wu K, Nasir A, et al. Interim report of the reactogenicity and immunogenicity of severe acute respiratory syndrome coronavirus 2 xbb&#x2013;containing vaccines. J Infect Dis. 2024;230(2):e279&#x2013;e286. doi:10.1093/infdis/jiae067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiae067</ArticleId><ArticleId IdType="pmc">PMC11326827</ArticleId><ArticleId IdType="pubmed">38349280</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus: circulation des variants du SARS-CoV-2. 2024. [Accessed 2024 Feb
29, at
https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/coronavirus-circulation-des-variants-du-sars-cov-2.).</Citation></Reference><Reference><Citation>Covid-19 et personnes immunod&#xe9;prim&#xe9;es: Le sort des personnes immunod&#xe9;prim&#xe9;es toujours suspendu &#xe0; la menace du risque infectieux. [Accessed 2024, 2024 May
1, at
https://www.astrazeneca.fr/Actualites/Covid-19-et-personnes-immunodeprimees.html.).</Citation></Reference><Reference><Citation>Wang X, Pahwa A, Bausch-Jurken MT, Chitkara A, Sharma p, Malmenas M, Vats S, Gordon Whitfield M, Zhi Hua Lai K, Dasari P , Gupta R. Comparative effectiveness of the mRNA-1273 and BNT162b2 COVID-19 vaccines among adults with underlying medical conditions: a systematic literature review and pairwise meta-analysis using GRADE. medRxiv 2024; 2024.09.13.24313632.</Citation></Reference><Reference><Citation>Marra AR, Kobayashi T, Callado GY, Pardo I, Gutfreund MC, Hsieh MK, Lin V, Alsuhaibani M, Hasegawa S, Tholany J, et al. The effectiveness of COVID-19 vaccine in the prevention of post-covid conditions: a systematic literature review and meta-analysis of the latest research. Antimicrob Steward Healthc Epidemiol. 2023;3(1):e168. doi:10.1017/ash.2023.447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ash.2023.447</ArticleId><ArticleId IdType="pmc">PMC10644173</ArticleId><ArticleId IdType="pubmed">38028898</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of COVID-19 vaccination on long covid: systematic review. BMJ Med. 2023;2(1):e000385. doi:10.1136/bmjmed-2022-000385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000385</ArticleId><ArticleId IdType="pmc">PMC9978692</ArticleId><ArticleId IdType="pubmed">36936268</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0; M, Mercad&#xe9;-Besora N, Kolde R, Trinh NTH, Roel E, Burn E, Rathod-Mistry T, Kostka K, Man WY, Delmestri A, et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir Med. 2024;12(3):225&#x2013;236. doi:10.1016/S2213-2600(23)00414-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00414-9</ArticleId><ArticleId IdType="pubmed">38219763</ArticleId></ArticleIdList></Reference><Reference><Citation>APCOVID-19 : &#xe9;tude nationale sur la pr&#xe9;valence et l&#x2019;impact de l&#x2019;affection post-COVID-19. 2023. [Accessed 2023, Dec
7, at
https://www.santepubliquefrance.fr/etudes-et-enquetes/apcovid-19-etude-nationale-sur-la-prevalence-et-l-impact-de-l-affection-post-covid-19.).</Citation></Reference><Reference><Citation>Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, Lewis N, Natarajan K, Stenehjem E, Grannis SJ, et al. Waning of vaccine effectiveness against moderate and severe COVID-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022;379:e072141. doi:10.1136/bmj-2022-072141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072141</ArticleId><ArticleId IdType="pmc">PMC9527398</ArticleId><ArticleId IdType="pubmed">36191948</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Feng S, Zhao Y, Wang H, Jiang H. Preferences for COVID-19 vaccines: systematic literature review of discrete choice experiments. JMIR Public Health Surveill. 2024;10:e56546. doi:10.2196/56546.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/56546</ArticleId><ArticleId IdType="pmc">PMC11319885</ArticleId><ArticleId IdType="pubmed">39073875</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautier S, Luyt D, Davido B, Herr M, Cardot T, Rousseau A, Annane D, Delarocque-Astagneau E, Josseran L. Cross-sectional study on COVID-19 vaccine hesitancy and determinants in healthcare students: interdisciplinary trainings on vaccination are needed. BMC Med Educ. 2022;22(1):299. doi:10.1186/s12909-022-03343-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12909-022-03343-5</ArticleId><ArticleId IdType="pmc">PMC9020813</ArticleId><ArticleId IdType="pubmed">35443661</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai R, Hervey J, Hoffman K, Wood J, Johnson J, Deighton D, Clermont D, Loew B, Goldberg SL. COVID-19 vaccine hesitancy and acceptance among individuals with cancer, autoimmune diseases, or other serious comorbid conditions: cross-sectional, internet-based survey. JMIR Public Health Surveill. 2022;8(1):e29872. doi:10.2196/29872.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/29872</ArticleId><ArticleId IdType="pmc">PMC8734610</ArticleId><ArticleId IdType="pubmed">34709184</ArticleId></ArticleIdList></Reference><Reference><Citation>Spikevax (previously COVID-19 vaccine moderna) COVID-19 mRNA vaccine. [Accessed 2024 Oct 2].</Citation></Reference><Reference><Citation>Evans RA, Dube S, Lu Y, Yates M, Arnetorp S, Barnes E, Bell S, Carty L, Graham S, Justo N. Impact of COVID-19 on immunocompromised populations during the omicron era: insights from the observational population-based INFORM study. In: The lancet regional health &#x2013;. Europe.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10730312</ArticleId><ArticleId IdType="pubmed">38115964</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurovac J, Barna M. mRNA-1273 vaccinated expenditure of hospitalisation analysis results. 03NOV2023. Moderna data on file.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>